240 related articles for article (PubMed ID: 27214767)
41. Evaluation of the efficacy and safety of etanercept 50 mg once weekly in Japanese patients with rheumatoid arthritis and comparison with 25 mg etanercept twice weekly.
Mochizuki T; Momohara S; Yano K; Shirahata T; Ikari K
Mod Rheumatol; 2013 Sep; 23(5):994-1000. PubMed ID: 23138447
[TBL] [Abstract][Full Text] [Related]
42. Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine.
Gremese E; Carletto A; Padovan M; Atzeni F; Raffeiner B; Giardina AR; Favalli EG; Erre GL; Gorla R; Galeazzi M; Foti R; Cantini F; Salvarani C; Olivieri I; Lapadula G; Ferraccioli G;
Arthritis Care Res (Hoboken); 2013 Jan; 65(1):94-100. PubMed ID: 22730143
[TBL] [Abstract][Full Text] [Related]
43. Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register.
Chatzidionysiou K; Kristensen LE; Eriksson J; Askling J; van Vollenhoven R;
Scand J Rheumatol; 2015; 44(6):431-7. PubMed ID: 26084325
[TBL] [Abstract][Full Text] [Related]
44. Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study.
van Mulligen E; de Jong PHP; Kuijper TM; van der Ven M; Appels C; Bijkerk C; Harbers JB; de Man Y; Molenaar THE; Tchetverikov I; Goekoop-Ruiterman YPM; van Zeben J; Hazes JMW; Weel AEAM; Luime JJ
Ann Rheum Dis; 2019 Jun; 78(6):746-753. PubMed ID: 30954969
[TBL] [Abstract][Full Text] [Related]
45. Necessity of TNF-alpha inhibitor discontinuation in rheumatoid arthritis is predicted by smoking and number of previously used biological DMARDs.
Cuppen BV; Jacobs JW; Ter Borg EJ; Marijnissen AC; Bijlsma JW; Lafeber FP; van Laar JM;
Clin Exp Rheumatol; 2017; 35(2):221-228. PubMed ID: 27749223
[TBL] [Abstract][Full Text] [Related]
46. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study.
Bartelds GM; Wijbrandts CA; Nurmohamed MT; Stapel S; Lems WF; Aarden L; Dijkmans BA; Tak PP; Wolbink GJ
Ann Rheum Dis; 2010 May; 69(5):817-21. PubMed ID: 19581278
[TBL] [Abstract][Full Text] [Related]
47. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study.
Tanaka Y; Takeuchi T; Mimori T; Saito K; Nawata M; Kameda H; Nojima T; Miyasaka N; Koike T;
Ann Rheum Dis; 2010 Jul; 69(7):1286-91. PubMed ID: 20360136
[TBL] [Abstract][Full Text] [Related]
48. Power Doppler ultrasonographic monitoring of response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis.
Naredo E; Möller I; Cruz A; Carmona L; Garrido J
Arthritis Rheum; 2008 Aug; 58(8):2248-56. PubMed ID: 18668537
[TBL] [Abstract][Full Text] [Related]
49. Investigating the link between disease activity and infliximab serum levels in rheumatoid arthritis patients.
Valor L; Hernández-Flórez D; de la Torre I; Del Río T; Nieto JC; González C; López-Longo FJ; Monteagudo I; Llinares F; Rosas J; Garrido J; Naredo E; Carreño L
Clin Exp Rheumatol; 2015; 33(6):805-11. PubMed ID: 26314759
[TBL] [Abstract][Full Text] [Related]
50. Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy.
Chang CY; Meyer RM; Reiff AO
Arthritis Care Res (Hoboken); 2015 May; 67(5):658-66. PubMed ID: 25220674
[TBL] [Abstract][Full Text] [Related]
51. Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study.
Kievit W; van Herwaarden N; van den Hoogen FH; van Vollenhoven RF; Bijlsma JW; van den Bemt BJ; van der Maas A; den Broeder AA
Ann Rheum Dis; 2016 Nov; 75(11):1939-1944. PubMed ID: 26764260
[TBL] [Abstract][Full Text] [Related]
52. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data.
Kievit W; Adang EM; Fransen J; Kuper HH; van de Laar MA; Jansen TL; De Gendt CM; De Rooij DJ; Brus HL; Van Oijen PC; Van Riel PC
Ann Rheum Dis; 2008 Sep; 67(9):1229-34. PubMed ID: 18174220
[TBL] [Abstract][Full Text] [Related]
53. Long-term real-life experience with rituximab in adult Finnish patients with rheumatoid arthritis refractory or with contraindication to anti-tumor necrosis factor drugs.
Valleala H; Korpela M; Hienonen-Kempas T; Immonen K; Lähteenmäki J; Uusitalo T; Komulainen R; Möttönen T; Hannonen P
J Clin Rheumatol; 2015 Jan; 21(1):24-30. PubMed ID: 25539430
[TBL] [Abstract][Full Text] [Related]
54. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose.
Raffeiner B; Botsios C; Ometto F; Bernardi L; Stramare R; Todesco S; Sfriso P; Punzi L
Clin Exp Rheumatol; 2015; 33(1):63-8. PubMed ID: 25535985
[TBL] [Abstract][Full Text] [Related]
55. Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial.
van Mulligen E; Weel AE; Hazes JM; van der Helm-van Mil A; de Jong PHP
Ann Rheum Dis; 2020 Sep; 79(9):1174-1181. PubMed ID: 32482645
[TBL] [Abstract][Full Text] [Related]
56. Long-term outcomes of treat-to-target strategy in established rheumatoid arthritis: a daily practice prospective cohort study.
de Andrade NPB; da Silva Chakr RM; Xavier RM; Viecceli D; Correa RHB; de Oliveira Filho CM; Brenol CV
Rheumatol Int; 2017 Jun; 37(6):993-997. PubMed ID: 28293776
[TBL] [Abstract][Full Text] [Related]
57. Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients.
van den Brandt S; Zbinden A; Baeten D; Villiger PM; Østensen M; Förger F
Arthritis Res Ther; 2017 Mar; 19(1):64. PubMed ID: 28320445
[TBL] [Abstract][Full Text] [Related]
58. Which patients with rheumatoid arthritis, spondyloarthritis, or juvenile idiopathic arthritis receive TNF-α antagonists in France? The CORPUS cohort study.
Saraux A; Benichou J; Guillevin L; Idbrik L; Job-Deslandre C; Sibilia J; Soudant M; Wendling D; Guillemin F
Clin Exp Rheumatol; 2015; 33(5):602-10. PubMed ID: 26315585
[TBL] [Abstract][Full Text] [Related]
59. Patient-tailored dose reduction of TNF-α blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice.
Arends S; van der Veer E; Kamps FB; Houtman PM; Bos R; Bootsma H; Brouwer E; Spoorenberg A
Clin Exp Rheumatol; 2015; 33(2):174-80. PubMed ID: 25797228
[TBL] [Abstract][Full Text] [Related]
60. Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice.
Backhaus M; Kaufmann J; Richter C; Wassenberg S; Roske AE; Hellmann P; Gaubitz M
Clin Rheumatol; 2015 Apr; 34(4):673-81. PubMed ID: 25630309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
